Last edition
News about "Piramal Pharma Solutions"
Piramal Pharma Solutions, the CDMO arm of Piramal Pharma Ltd., has installed a state-of-the-art Korsch XM-12 bilayer tablet press at its Morpeth, UK facility to enhance precision, efficiency, and flexibility in oral solid manufacturing.
Piramal Pharma Solutions | 16/09/2025 | By Mrinmoy Dey
Piramal Pharma Solutions leveraged its CDMO expertise to help George Medicines develop WIDAPLIK, the first and only FDA-approved triple combination therapy for hypertension, combining telmisartan, amlodipine, and indapamide to effectively lower blood pressure.
Piramal Pharma Solutions | 01/09/2025 | By Mrinmoy Dey
Piramal Pharma, NewAmsterdam Launch Dedicated OSD Suite at Sellersville Site in US
Piramal Pharma Solutions and NewAmsterdam Pharma have inaugurated a dedicated oral solid dosage (OSD) suite at Piramal’s Sellersville, Pennsylvania facility to support the production of NewAmsterdam’s investigational fixed-dose combination cholesterol therapy.
Piramal Pharma Solutions | 21/08/2025 | By Mrinmoy Dey
Piramal Pharma to Invest USD 80 Million for Expansion of Sterile Injectables Facility in Kentucky
The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new laboratory, and state-of-the-art machinery to scale clients’ products effectively.
Piramal Pharma Solutions | 01/10/2024 | By Aishwarya | 553
Piramal Pharma Solutions announces production first batches at new API facility in Michigan
The initial production run is the culmination of capital expenditure of $38 million in equipment and construction costs
<br />
Piramal Pharma Solutions | 20/02/2023 | By Sudeep Soparkar | 814
Piramal Pharma Solutions launches ADCelerate
ADCelerate is a new, branded solution for antibody-drug conjugate drug development
Piramal Pharma Solutions | 13/10/2022 | By Sudeep Soparkar | 402
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy